BIOMARIN PHARMACEUTICAL INC BMRN

BioMarin’s strongest current fact is the first-quarter filing set rather than the June governance filing trail. In the SEC EDGAR 10-Q for the period ending 2026-03-31, BIOMARIN PHARMACEUTICAL INC reported revenue from contracts with customers, excluding assessed tax, of $766.2M, operating income of $129.6M, net income attributable to parent of $105.5M, and diluted EPS of $0.54 on 197.7M diluted weighted average shares.

This is a pharmaceutical operating company, and the supplied product rail is direct: the 10-Q extract includes net product revenues and says the company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The filing extract also shows net product revenue lines of $760,078 and $734,644, plus another supplied net product revenue line of $(12,412) and $12,545, which ties the company story to product sales rather than a detached corporate slogan.

The balance sheet and cash facts give the quarter its spine. At 2026-03-31, BioMarin had $8.59B of assets, $2.38B of liabilities, $6.21B of stockholders’ equity attributable to parent and $2.22B of cash and cash equivalents. Net cash provided by operating activities was $220.7M, payments to acquire property, plant and equipment were $20.9M, research and development expense was $178.8M, inventory, net, was $1.27B, and inventories decreased by $44.5M.

The supplied source route is SEC-led: the rail includes the SEC EDGAR filing index, SEC submissions JSON, SEC companyfacts JSON, the 2026-05-05 10-Q, the 2026-05-04 earnings 8-K, the 2026-06-04 Annual Meeting 8-K and six Form 4 filings dated 2026-06-04. It does not include a TradingView or chart route, so this report does not invent candles, levels, moving averages or price action. The market mechanism here is the public filing record: product revenue, cash, R&D, inventory, operating cash flow, governance votes and Form 4 filing activity.

What changed in the supplied public record is concrete. On 2026-05-04, BioMarin announced financial results for its first quarter ended 2026-03-31 through an SEC EDGAR 8-K. On 2026-06-04, the company filed an 8-K saying stockholders approved an amendment to the BioMarin Pharmaceutical Inc. plan at the Annual Meeting, after the Compensation Committee had previously approved it subject to stockholder approval, and also approved named executive officer compensation on an advisory basis.

The evidence is useful, but narrow. It does not supply named product-level sales, guidance, pipeline milestones, share-price context, dividend or buyback facts, the detailed contents of the six Form 4 filings, or a chart source. The current file therefore proves a profitable, cash-rich quarter with product-revenue exposure and fresh governance filings; it does not prove market sentiment, valuation, product mix or future approval timing.